Form 8-K BioScrip, Inc. For: May 14

May 16, 2018 5:02 PM

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

May 14, 2018

  

BIOSCRIP, INC.

(Exact name of registrant as specified in its charter)

  

Delaware

001-11993

05-0489664

(State or other jurisdiction of incorporation)

 (Commission File Number)

 (Employer Identification Number)

 

 

1600 Broadway, Suite 700, Denver, Colorado 80202

(Address of principal executive offices)

 

(720) 697-5200

(Registrant's telephone number, including area code)

 

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

    Emerging growth company  

¨

           

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

  ¨

 

 

 

 

 

Item 5.02   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 14, 2018, Anthony Lopez stepped down as Chief Accounting Officer of BioScrip, Inc. Alex Schott, BioScrip’s Interim Chief Accounting Officer, will remain in that position until a new Chief Accounting Officer is appointed

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  BIOSCRIP, INC.
   
Date: May 14, 2018  
   
  By:  /s/ Kathryn M. Stalmack
    Kathryn M. Stalmack
Senior Vice President, General Counsel and Secretary

 

 

 

 

Categories

SEC Filings